Mesenchymal Stem Cells Industry Overview
The global mesenchymal stem cells market size was valued at USD 2.4 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 12.6% from 2021 to 2028. An exponential rise in mesenchymal stem cell (MSC) based research and its implications in the field of regenerative medicine fuel the growth of the market. The constantly evolving landscape of stem cell therapies is also expected to propel investments in the MSC market space; large-scale operational entities are targeting small or emerging players with an operating strategy of acquisition in order to boost their market presence.
The strong pipeline of mesenchymal stem cell-based products coupled with emerging applications of mesenchymal stem cells is anticipated to accelerate the market growth. As of 2019, 10 mesenchymal stem cells based products have received approval from regulatory bodies across the world. Moreover, a substantial number of companies are exploring the potential of MSCs as therapeutics targeted at the treatment of inflammatory disorders, in turn boosting the market growth.
Gather more insights about the market drivers, restraints and growth of the Global Mesenchymal Stem Cells market
For instance, Takeda/TiGenix phase 3 clinical trial incorporates MSCs for complex perianal fistulas in Crohn's Disease. This is the most successful late-stage clinical trial as of September 2020. These factors are anticipated to bolster the usage of MSC products offered by key market entities, thereby intensifying the market competition. The recent pandemic outbreak of COVID-19 has driven the focus of the scientific community and industry participants towards the development of MSC-based therapeutics. The immunomodulation property of MSCs makes them a potential therapeutic approach to prevent respiratory infection caused by COVID-19.
As of July 2020, more than 50 clinical trials have been reported to incorporate MSCs in the development of therapeutics associated with SARS-CoV-2 infection. Additionally, an increasing number of research activities around the development of novel vaccine platforms, involve MSCs. For instance, in June 2020, a group of research professionals in China described a novel approach for designing COVID-19 vaccines based on engineered human MSCs, with promising as well as favorable antibody response.
The majority of the mesenchymal stem cell applications are oriented towards research and clinical settings with comparatively lesser penetration across commercial applications. This is primarily attributed to the lack of standardized and regulated delivery of stem cell therapies; and ethical as well as safety concerns associated with human MSCs. Developments in the regulations and standardization of the mesenchymal stem cell industry are imperative to maintain market growth.
Browse through Grand View Research's Healthcare Industry Related Reports
Tissue Engineering Market - The global tissue engineering market size was computed at USD 9.9 billion in 2019 and is expected to witness a CAGR of 14.2% from 2020 to 2027.
Regenerative Medicine Market - The global regenerative medicine market size was valued at USD 27.29 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 11.27% from 2021 to 2027.
Mesenchymal Stem Cells Industry Segmentation
Grand View Research has segmented the global mesenchymal stem cells market on the basis of products and services, type, source of isolation, indication, application, and region:
Mesenchymal Stem Cells Products & Services Outlook (Revenue, USD Million, 2017 - 2028)
- Products
- Services
Mesenchymal Stem Cells Type Outlook (Revenue, USD Million, 2017 - 2028)
- Autologous
- Allogeneic
Mesenchymal Stem Cells Source of Isolation Outlook (Revenue, USD Million, 2017 - 2028)
- Bone Marrow
- Cord Blood
- Peripheral Blood
- Fallopian Tube
- Fetal Liver
- Lung
- Adipose Tissues
Mesenchymal Stem Cells Indication Outlook (Revenue, USD Million, 2017 - 2028)
- Bone And Cartilage Repair
- Cardiovascular Disease
- Inflammatory And Immunological Diseases
- Liver Diseases
- Cancer
- GvHD
- Others
Mesenchymal Stem Cells Application Outlook (Revenue, USD Million, 2017 - 2028)
- Disease Modelling
- Drug Development & Discovery
- Stem Cell Banking
- Tissue Engineering
- Toxicology Studies
- Others
Mesenchymal Stem Cells Regional Outlook (Revenue, USD Million, 2017 - 2028)
- North America
- Europe
- Asia Pacific
- Latin America
- MEA (Middle East & Africa)
Market Share Insights:
August 2019: Bayer AG invested USD 600 million to acquire BlueRock Therapeutics to strengthen its market presence in stem cell therapies. Such notable mergers and acquisitions are anticipated to support market growth.
Key Companies profiled:
Some prominent players in the global Mesenchymal Stem Cells Industry include
- Thermo Fisher Scientific, Inc.
- Cell Applications, Inc.
- Cyagen Biosciences Inc.
- Axol Biosciences Ltd.
- Cytori Therapeutics Inc
- STEMCELL Technologies Inc
- Celprogen Inc
Order a free sample PDF of the Mesenchymal Stem Cells Market Intelligence Study, published by Grand View Research.
No comments:
Post a Comment